Helicobacter pylori Eradication: Equivalence Trials and the Optimal Duration of Therapy

Vakil, Nimish; Connor, Jason T.

doi:10.1111/j.1572-0241.2005.50615.x

Cited by 13 publications

(5 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A longer duration of treatment (14 days vs. 7 days) may prove more effective in curing infection but this hypothesis remains controversial 3, 40–45 . Asia Pacific and Japanese consensus reports recommended a 7‐day PPI‐based triple therapy 43, 44 .…”

Section: Discussionmentioning

confidence: 99%

Randomised clinical trial: the efficacy of a 10-day sequential therapy vs. a 14-day standard proton pump inhibitor-based triple therapy for Helicobacter pylori in Korea

Kim

Yoon

et al. 2011

Alimentary Pharmacology &Amp; Therapeutics

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

Randomised clinical trial: the efficacy of a 10-day sequential therapy vs. a 14-day standard proton pump inhibitor-based triple therapy for Helicobacter pylori in Korea

Kim

Yoon

et al. 2011

Alimentary Pharmacology &Amp; Therapeutics

View full text Add to dashboard Cite

show abstract

“…Standard triple-drug therapy-clarithromycin, amoxicillin, and a PPI twice daily for 14 days-has only an 83%-92% eradication rate at 1 year, and ulcers routinely recur in patients that fail treatment. 55 Notably, a recent randomized trial suggests that sequential therapy with 5 days of twice-daily pantoprazole and amoxicillin, followed by 5 days of twice-daily pantoprazole, clarithromycin, and tinidazole, may achieve a higher eradication rate than the former regimen, particularly in patients infected with clarithromycin-resistant H. pylori strains. 56 Additional risk factors for ulcer disease in patients using NSAIDs not included in the ACG guidelines, such as SSRI, antiplatelet agent, bisphosphonate, or chemotherapeutic agent usage, tobacco or cocaine abuse, psychological stress, or CMV or HSV infection may also be modifi able or treatable in selected cases.…”

Section: Gastro-protective Strategiesmentioning

confidence: 99%

Prevention of nonsteroidal anti-inflammatory drug-induced gastropathy

Schlansky

Hwang

2009

J Gastroenterol

View full text Add to dashboard Cite

Nonsteroidal anti-inflammatory drugs (NSAIDs) are widely used for their analgesic, antipyretic, and antiinflammatory properties, and aspirin is increasingly employed in the primary and secondary prevention of cardiovascular disease and ischemic stroke. Despite undisputed therapeutic efficacy for these indications, all NSAIDs impart a considerable risk of peptic ulcer disease and upper gastrointestinal hemorrhage. A growing body of evidence supports an association between non-aspirin NSAIDs and acute coronary syndromes, and an expanding understanding of the gastroduodenal effects of aspirin, COX-2 selective agents, clopidogrel, and Helicobacter pylori synergism fuel controversies in NSAID use. In this review, we discuss risk stratification of patients taking NSAIDs and the appropriate application of proven gastro-protective strategies to decrease the incidence of gastrointestinal hemorrhage based upon an individualized assessment of risk for potential toxicities. Prevention of NSAID-related gastropathy is an important clinical issue, and therapeutic strategies for both the primary and secondary prevention of adverse events are continually evolving.

show abstract

“…Our patient received metronidazole as part of a Helicobacter pylori eradication therapy using 40 mg pantoprazole once daily, 500 mg clarithromycin twice daily, and 500 mg metronidazole twice daily for 2 weeks [4], thus providing an adequate treatment also for Giardia lamblia infection [3,4]. Two months later, the patient was well without diarrhea or edema, and his weight had returned to normal.…”

Section: Case Reportmentioning

confidence: 99%

An exotic cause of exudative enteropathy

Tsourdi¹,

Heidrich

Winzer³

et al. 2014

Am J Case Rep

View full text Add to dashboard Cite

Patient: Male, 50Final Diagnosis: Exudative enteropathySymptoms: Abdominal pain • diarrhea • fever • hyponatremia • lymphadenopathy • weight lossMedication: —Clinical Procedure: —Specialty: —Objective:Unusual clinical courseBackground:Protein-losing enteropathy is a rare cause of hypoproteinemia. Erosive and non-erosive gastrointestinal diseases as well as vascular disorders that result in increased central venous pressure or mesenteric lymphatic obstruction may result in protein loss via the gastrointestinal tract.Case Report:We present the case of a 50-year-old man with protein-losing enteropathy, who had profuse diarrhea, abdominal pain, lymphadenopathy, fever, and a weight loss of 10 kg in the preceding 2 months. Extensive work-up revealed infection with Giardia lamblia. We review clinical signs and symptoms, laboratory findings, and imaging studies, and discuss potential pitfalls in establishing the diagnosis.Conclusions:To the best of our knowledge, this represents one of the few published cases of intestinal giardiasis as a cause of protein-losing enteropathy in an immunocompetent adult. The diagnosis of lambliasis should be based on a combination of stool cultures and serum serology, and in cases of high clinical suspicion, an endoscopy and biopsy of the upper GI tract is recommended.

show abstract

Helicobacter pylori Eradication: Equivalence Trials and the Optimal Duration of Therapy

Cited by 13 publications

References 11 publications

Randomised clinical trial: the efficacy of a 10-day sequential therapy vs. a 14-day standard proton pump inhibitor-based triple therapy for Helicobacter pylori in Korea

Randomised clinical trial: the efficacy of a 10-day sequential therapy vs. a 14-day standard proton pump inhibitor-based triple therapy for Helicobacter pylori in Korea

Prevention of nonsteroidal anti-inflammatory drug-induced gastropathy

An exotic cause of exudative enteropathy

Contact Info

Product

Resources

About